The company is currently conducting clinical trials of its device to treat depression.
Brainsway Ltd. (TASE:BRIN) has obtained a permit to conduct Phase I human clinical trials for use of its magnetic neurological treatment to treat Parkinson’s disease.
The company is currently conducting clinical trials of its device to treat cases of depression in which current pharmacological drugs cannot help. The company reported interim results of this trial a few months ago.
Published by Globes [online], Israel business news - www.globes.co.il - on July 17, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007